Latest Insider Transactions at Veracyte, Inc. (VCYT)
This section provides a real-time view of insider transactions for Veracyte, Inc. (VCYT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERACYTE, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERACYTE, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 10
2021
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Indirect |
1,900
-0.86%
|
$95,000
$50.03 P/Share
|
|
Sep 08
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
926
-1.82%
|
$46,300
$50.53 P/Share
|
|
Sep 07
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
12,531
-9.96%
|
$626,550
$50.88 P/Share
|
|
Sep 07
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,531
+6.59%
|
$200,496
$16.96 P/Share
|
|
Sep 02
2021
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,288
-3.42%
|
$118,976
$52.97 P/Share
|
|
Sep 02
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
912
-1.76%
|
$47,424
$52.97 P/Share
|
|
Aug 02
2021
|
Karin Eastham Director |
SELL
Open market or private sale
|
Indirect |
4,400
-29.22%
|
$193,600
$44.06 P/Share
|
|
Jul 19
2021
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
34,000
+50.0%
|
-
|
|
Jun 23
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
4,375
-7.78%
|
$170,625
$39.75 P/Share
|
|
Jun 23
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,375
+7.22%
|
$105,000
$24.69 P/Share
|
|
Jun 08
2021
|
Karin Eastham Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,720
+50.0%
|
-
|
|
Jun 08
2021
|
John L Bishop Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,720
+50.0%
|
-
|
|
Jun 08
2021
|
Evan/ Fa Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,720
+18.38%
|
-
|
|
Jun 08
2021
|
Jens Holstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,720
+44.86%
|
-
|
|
Jun 08
2021
|
Kevin K Gordon Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,720
+50.0%
|
-
|
|
Jun 08
2021
|
Robert S Epstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,720
+50.0%
|
-
|
|
Jun 04
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
9,081
-5.2%
|
$308,754
$34.28 P/Share
|
|
Jun 04
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,156
+6.47%
|
$106,028
$13.1 P/Share
|
|
Jun 03
2021
|
Jens Holstein Director |
BUY
Open market or private purchase
|
Direct |
2,000
+50.0%
|
$70,000
$35.19 P/Share
|
|
Jun 02
2021
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,288
-1.19%
|
$82,368
$36.07 P/Share
|
|
Jun 02
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
912
-1.7%
|
$32,832
$36.07 P/Share
|
|
Jun 01
2021
|
Marc Stapley Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,807
+50.0%
|
-
|
|
May 17
2021
|
Bonnie H Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,065
+6.83%
|
$70,325
$5.61 P/Share
|
|
May 17
2021
|
Beverly Jane Alley VP, Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
5,500
+29.73%
|
-
|
|
May 03
2021
|
Karin Eastham Director |
SELL
Open market or private sale
|
Indirect |
4,427
-12.04%
|
$216,923
$49.01 P/Share
|
|
Mar 19
2021
|
Muna Bhanji Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,541
+50.0%
|
-
|
|
Mar 04
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
52,015
-7.08%
|
$2,652,765
$51.39 P/Share
|
|
Mar 04
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,970
+7.36%
|
$433,580
$14.98 P/Share
|
|
Mar 02
2021
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
6,320
-3.43%
|
$391,840
$62.15 P/Share
|
|
Mar 02
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,995
-7.42%
|
$371,690
$62.15 P/Share
|
|
Mar 02
2021
|
Keith Kennedy COO / CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,783
-4.72%
|
$358,546
$62.15 P/Share
|
|
Mar 02
2021
|
Mark Ho |
SELL
Payment of exercise price or tax liability
|
Direct |
490
-0.68%
|
$30,380
$62.15 P/Share
|
|
Feb 26
2021
|
Bonnie H Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+9.79%
|
-
|
|
Feb 26
2021
|
Iii James H Erlinger |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+50.0%
|
-
|
|
Feb 26
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+13.4%
|
-
|
|
Feb 26
2021
|
Keith Kennedy COO / CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+10.9%
|
-
|
|
Feb 25
2021
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
6,250
-77.95%
|
$375,000
$60.96 P/Share
|
|
Feb 25
2021
|
Karin Eastham Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+50.0%
|
$25,000
$4.0 P/Share
|
|
Feb 24
2021
|
Bonnie H Anderson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
39,488
-19.38%
|
$2,448,256
$62.3 P/Share
|
|
Feb 24
2021
|
Keith Kennedy COO / CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,046
-9.31%
|
$684,852
$62.3 P/Share
|
|
Feb 24
2021
|
Giulia C Kennedy Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,048
-12.83%
|
$622,976
$62.3 P/Share
|
|
Jan 22
2021
|
Evan/ Fa Jones Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+14.29%
|
$10,000
$2.36 P/Share
|
|
Jan 20
2021
|
Mark Ho |
BUY
Exercise of conversion of derivative security
|
Direct |
52,500
+25.41%
|
$262,500
$5.7 P/Share
|
|
Jan 13
2021
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Direct |
18,541
-4.25%
|
$927,050
$50.95 P/Share
|
|
Jan 13
2021
|
Bonnie H Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
18,541
+7.7%
|
$92,705
$5.61 P/Share
|
|
Jan 12
2021
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Direct |
20,354
-3.08%
|
$1,017,700
$50.42 P/Share
|
|
Jan 12
2021
|
Bonnie H Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,354
+8.33%
|
$101,770
$5.61 P/Share
|
|
Jan 11
2021
|
Bonnie H Anderson Director |
SELL
Open market or private sale
|
Direct |
71,105
-9.43%
|
$3,555,250
$50.76 P/Share
|
|
Jan 11
2021
|
Bonnie H Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
71,105
+10.81%
|
$497,735
$7.24 P/Share
|
|
Jan 04
2021
|
Kevin K Gordon Director |
SELL
Open market or private sale
|
Direct |
10,000
-72.39%
|
$480,000
$48.95 P/Share
|